|Articles|April 26, 2022
Daily Medication Pearl: Tamsulosin (Flomax)
Author(s)Saro Arakelians, PharmD
Tamsulosin (Flomax) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.
Advertisement
Medication Pearl of the Day: Tamsulosin (Flomax)
Indication: Tamsulosin (Flomax) is an alpha1 adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.
Insight:
- Dosing: 0.4 mg once daily taken approximately one-half hour following the same meal each day.
- Dosage forms: Capsules 0.4 mg.
- Adverse events: The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, nausea, sinusitis, insomnia, libido decreased, tooth disorder, and blurred vision.
- Mechanism of action: Tamsulosin, an alpha1 adrenoceptor blocking agent, exhibits selectivity for alpha1 receptors in the human prostate. At least 3 discrete alpha1 adrenoceptor subtypes have been identified: alpha1A, alpha1B, and alpha1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1 receptors in human prostate are of the alpha1A subtype.
- Manufacturer: Boehringer Ingelheim
Reference
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020579s026lbl.pdf
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5